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Summary
Questions under study/principles: Interest groups
advocate centre-specific outcome data as a useful
tool for patients in choosing a hospital for their
treatment and for decision-making by politicians
and the insurance industry. Haematopoietic stem
cell transplantation (HSCT) requires significant
infrastructure and represents a cost-intensive pro-
cedure. It therefore qualifies as a prime target for
such a policy.
Methods: We made use of the comprehensive
database of the Swiss Blood StemCells Transplant
Group (SBST) to evaluate potential use of mortal-
ity rates.Nine institutions reported a total of 4717
HSCT – 1427 allogeneic (30.3%), 3290 autolo-
gous (69.7%) – in 3808 patients between the years
1997 and 2008. Data were analysed for survival-
and transplantation-related mortality (TRM) at
day 100 and at 5 years.
Results: The data showed marked and signifi-
cant differences between centres in unadjusted
analyses. These differences were absent or mar-
ginal when the results were adjusted for disease,
year of transplant and the EBMT risk score (a
score incorporating patient age, disease stage, time
interval between diagnosis and transplantation,
and, for allogeneic transplants, donor type and do-
nor-recipient gender combination) in a multivari-
able analysis.
Conclusions:These data indicate compara-
ble quality among centres in Switzerland. They
show that comparison of crude centre-specific
outcome data without adjustment for the patient
mix may be misleading.Mandatory data collection
and systematic review of all cases within a compre-
hensive quality management system might, in
contrast, serve as a model to ascertain the quality
of other cost-intensive therapies in Switzerland.
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Introduction
The first reports of successful haematopoietic
stem cell (HSCT) transplantation date back more
than fifty years [1].After a long experimental phase,
HSCT has become standard care for many patients
with nonmalignant congenital or acquired disor-
ders of the haematopoietic system or with haema-
tological malignancies.HSCThas undergone rapid
expansion and constant development in technology
of use over the last two decades. Novel indications
such as autoimmune disorders or single enzyme de-
ficiencies are currently under evaluation. Bone
marrow, peripheral blood and cord blood are avail-
able as stem cell sources. More than 13 million
typed volunteer donors worldwide (www.world
marrow.org) provide stem cells for patients without
family donors. Novel conditioning regimens have
extended the use of HSCT to older patients or to
those with comorbidities [1–6].
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Major progress in supportive care measures
and transplant application has significantly im-
proved results over time. Nonetheless, HSCT re-
mains associated with significant morbidity and
mortality.Also,HSCT is a prototype for high cost,
highly specialised medicine. It requires significant
infrastructure and a network of specialists [7–10].
It is understandable that quality and cost issues are
of major concern to transplant teams, patients, ad-
vocacy groups, referring physicians, health care
providers, hospitals and politicians. The desire to
obtain high quality treatment at reasonable cost,
while ensuring access to transplant centres for pa-
tients, contrasts with the reality of limited re-
sources and the need for a minimal volume of
workload to ascertain quality. It is understandable
that the provision of funds is linked to the request
for outcome reporting. The C.W. Bill Young
Transplantation act in the USA (www.hrsa.gov)
has set an example.
Even though the utility of data on outcome is
undeniable when deciding on allocation of funds,
the reality is more complex. Many systems for
analysis and reporting of data have been proposed,
coming primarily from the field of surgical inno-
vations [11–15]. All approaches discuss the publi-
cation of mortality rates as one possible way to im-
prove outcome, to guide patients in their selection
of medical care providers and to aid decision-mak-
ing at the political level.While all stress the need
for standardised evaluation, no single measure has
been recognised as valid for all situations [16–19].
Public reporting is accepted as a standard during
early introduction of new methods in fields with
previously inadequate access [20, 21] or for some
high volume procedures [11–15]. Its value in or-
gan transplantation or HSCT remains a matter of
debate. The same applies to the minimal number
of procedures required for safe application.There
is universal agreement that “learning curves” ap-
ply to manual as well as complex intellectual pro-
cedures, and that higher case loads accelerate and
facilitate learning [22–28]. It is also generally ac-
cepted that differences in outcome exist between
centres. Whether these differences are due to the
volume of procedures or to “centre effects” re-
flecting local policies remains controversial [29–
33]. In most of the recent evaluations of centre ef-
fects from different fields of medicine, differences
between centres were primarily the consequence
of variations in case mix [34–45].
In response to a relevant comment from the
reviewer we have phrased the statement with
greater care and balance. Publication of mortality
rates is proposed by some as a criterion for quality
control, despite its limited evidence [9–12]. Cen-
tre-specific mortality rates have also been re-
quested by the recently established commission
for highly specialised medicine in Switzerland.
Outcome could be one of several criteria in this
commission’s decision making process (www.gdk-
cds.ch/fileadmin/pdf/Themen/Gesundheitsversor
gung/Hochspezialisierte_Medizin/Geschregl-CICO
MS-1–7–d.pdf). The stem cell transplant collabo-
rative group (SBST) in Switzerland was con-
fronted with the same question more than 10 years
ago. The decision made at that time was to com-
mit all centres to the standardised European qual-
ity management system JACIE (www.jacie.org)
[46–48] and to mandatory reporting of all proce-
dures to an evaluation registry. The availability of
this comprehensive database with sufficient fol-
low-up provides the opportunity to test the value
of centre-specific outcome reporting within one
country.
Patients and methods
Study design
This is a retrospective observational data analysis
based on the prospective evaluation registry of the Swiss
Blood StemCellsTransplant Group (SBST).The registry
has been operational since 1997 and is based on the elec-
tronic database management system PROMISE of the
European Group for Blood and Marrow Transplantation
EBMT (http://www.ebmt.org). All teams performing
HSCT in Switzerland (table 1) have committed them-
selves to reporting to the SBST database. They are re-
quired by law to report all transplant outcomes and to ad-
here to the comprehensive quality management system
JACIE (www. Jacie.org). Hence the SBST data registry is
unique in capturing 100% of all HSCT in Switzerland
performed in public institutions.
All patients were required to give informed consent
and all teams were required to have institutional review
board approval for their transplant protocols.
Data collection and data validation
Data collection included basic information on dis-
ease, disease stage, patient and donor characteristics, do-
nor type, stem cell source, date of transplant and outcome.
Data were submitted at the time of transplant, either elec-
tronically or in paper form, and updated annually. Basic
information on outcome included time of last follow-up,
survival status, presence or absence of relapse and, if the
patient died, cause of death.
Data were validated by different independent sys-
tems; through confirmation by the reporting team, which
received a computer printout of the entered data, by se-
lective comparison with the EBMT activity survey [27],
by the regular JACIE audits or by selected on-site visits
through the EBMT quality control programme (www.
ebmt.org).
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Patient population
The analysis includes all patients receiving an HSCT
in Switzerland in one of the nine institutions (table 1) be-
tween 1997, when the SBST database was established, and
2008. Consequently, a minimum follow-up of three
months is available. Some patients received more than
one transplant and some received both autologous and al-
logeneic transplants. A few patients have received a trans-
plant for different diseases during the evolution over time.
By design of the database, patients with a first allogeneic
or first autologous HSCT were counted as patients, all
subsequent procedures as additional transplants: by defi-
nition, there were more procedures than transplants and
more “patients” with a first transplant than patients.
There were 4717 HSCT in 3656 patients. Of these,
152 received both a first autologous and a first allogeneic
HSCT.Hence a total of 3808 patients received a first allo-
geneic (1273) or first autologous (2535) HSCT. There
were 1061 additional transplants (306 allogeneic, 755 au-
tologousHSCT).Of these 864 received a 2ndHSCT (237
allogeneic and 627 autologous HSCT), 189 a 3rd HSCT
(65 allogeneic and 124 autologous HSCT) and 8 a 4th
HSCT (4 allogeneic and 4 autologous HSCT). The basic
characteristics of the 4717 HSCT are listed in table 1.
There were significantly more male patients with a trans-
plant (2916, 61.8%).The median age of all patients was 48
years (range 0.16–76.6 years). Patients with autologous
HSCT were significantly older (median 51.5 years, range
0.66 to 76.6 years) than patients with an allogeneic HSCT
(median 39.9 years, range 0.16 to 69.9 years; p = 0.0001).
Of the total of 4717 transplants, 1427 (30.3%) were
allogeneic and 3290 (69.7%) autologous. Main indica-
tions for a transplant were lymphoproliferative disorderswith
2513 transplants (53%), 193 patients with allogeneic
HSCT (8%), 2320 with autologous HSCT (92%); leukae-
miaswith 1365 transplants (28.9%), 1084 patients with al-
logeneic (79%), 281 with autologous (21%) HSCT; solid
tumours with 687 transplants (14.5%), 10 with allogeneic
HSCT (1%), 677 with autologous HSCT (99%) and non-
malignant disorders with 152 transplants (3.2%), 140 with
allogeneic HSCT (92%) and 12 with autologous HSCT
(8%).
The most frequent indication for an allogeneic
HSCT for a malignancy was acute myeloid leukaemia,
with 369 HSCT for this disease (33% of all allogeneic
HSCT). The most frequent indication for an allogeneic
HSCT for nonmalignant disease was a bone marrow fail-
ure syndrome with 54 HSCT (5% of all allogeneic
HSCT). In contrast, the most frequent indication for an
autologous HSCTwas a plasma cell disorder with 922 pa-
tients (36% of all autologous HSCT). Autologous HSCT
for nonmalignant indications were 12 in number and pri-
marily restricted to autoimmune disorders (N = 11).
Statistical analysis
Differences in patient population between centres
were analysed by the Kruskal Wallis test for continuous
and the chi-squared for categorical variables. Survival was
analysed by the Kaplan Meier estimator.Transplantation-
related mortality was defined as death before relapse and
was assessed as cumulative incidence, competing with the
risk of relapse. Backward stepwise Cox regression models
were used for the multivariable analyses, forcing in trans-
plant centre and retaining EBMT risk score (composed of
patient of patient, disease stage, time interval from diag-
nosis to transplant for all HSCT; donor type and in addi-
tion donor recipient gender combination for allogeneic
HSCT) (49, 50), and year of transplant if significantly as-
sociated with the outcome under study. Given multiple
comparisons a p value of <0.01 was considered statistically
significant.
Table 1
Key characteristics of 4717 HSCT performed in Switzerland from 1997 to 2008.
Allogeneic Autologous Total
N % */** N % N %
N
1st HSCT (patients) 1273 33.4** 2535 66.6** 3808 80.7*
Total HSCT 1427 30.3** 3290 69.7** 4717 100
Gender
Male N (%) 871 61* 2045 62* 2916 61.8*
Female N (%) 556 39* 1245 38* 1801 38.2*
Age
Median (range) 39.9 51.5 48
range (0.16–69.9) (0.66–76.6) (0.16–76.6)
Centres**
Aarau – 280 100 280 5.9
Basel 619 63.6 355 36.4 974 20.6
Bellinzona – 202 100 202 4.3
Bern – 591 100 591 12.5
Geneva 344 94.2 21 5.8 365 7.7
Lausanne – 888 100 888 18.8
St. Gallen – 207 100 207 4.4
Zurich adult 316 31.3 695 68.7 1011 21.4
Zurich paediatrics 148 74.4 51 25.6 199 4.2
Main disease indications**
Leukaemias 1084 79.4 281 20.6 1365 28.9
Lymphomas 193 7.7 2320 92.3 2513 53.3
Nonmalignant disorders 140 92.1 12 7.9 152 3.2
Solid tumours 10 1.5 677 98.5 687 14.6
Stem cell source**
Bone marrow 368 94.6 21 5.4 389 8.2
Peripheral blood 1022 23.8 3269 76.2 4291 91.0
Cord blood 37 100 0 0 37 0.8
Donor type*
Syngeneic 28 2.0
HLA-identical sibling 790 55.4 n.a. n.a. n.a. n.a.
Other family donor 143 10.0
Unrelated donor 466 32.7
Year of transplant**
1997–2003 708 28.1 1810 71.9 2518
2004–2008 719 32.7 1480 67.3 2199
EBMT risk score*
0 39 2.7 12 0.4
1 155 10.9 93 2.8
2 324 22.7 587 17.8
3 317 22.2 1309 39.8 n.a. n.a.
4 297 20.8 986 30.0
5 220 15.4 303 9.2
6 70 4.9
7 5 0.4
Days in hospital (SVK)***
N HSCT 656 1571 2227
75 percentile 26–70 15–28 15–49
* Column percentage, ** Row percentage, *** For years 2003–2008 only
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Differences in patient population between
centres
There were significant differences in the pa-
tient population between the nine transplant cen-
tres (table 2). Four centres performed allogeneic
HSCT, one of them allogeneic HSCT exclusively.
Autologous HSCT were performed in eight cen-
tres, in three combined with allogeneic HSCT.
Paediatric transplants, defined as HSCT in pa-
tients under 18 years, were performed in five cen-
tres, allogeneic paediatric HSCT in 3, autologous
paediatric HSCT in 3; hence age distribution dif-
fered significantly between the centres, with a me-
dian age range from 7 years to 51 years and an ab-
solute range from 0.2 to 77 years.
There were significant differences in the dis-
tribution of the main indications. Lymphoprolif-
erative disorders were the main indications in cen-
tres with autologous HSCT, leukaemia in centres
with allogeneic HSCT and nonmalignant, mainly
congenital disorders in the only exclusively paedi-
atric centre. There were significant differences in
the EBMT risk score among centres performing
allogeneic HSCT (p <0.0001). There was a signif-
icant difference in the duration of hospital stay,
with a median hospitalisation of 19 days (range
0–438 days) for autologous and of 42 days (range
0–389 days) for allogeneic HSCT. It is of interest
to note that paediatric patients (median 56 days,
range 5–247 days) were in hospital significantly
longer than adult patients (median 21 days, range
0–438 days).
Survival and transplantation-related mortality
At the time of analysis (July 2009), 2287 of the
3808 patients were alive (60.1%), 1420 had died
(37.3%), in 344 mortality was transplantation-re-
lated (24%), in 1076 patients (76%) the cause was
relapse of malignant disease. Ninety-three pa-
tients (2.4%) were lost to follow-up, in 8 (0.2%)
Results
Table 2
Main indications and HSCT characteristics by transplant centre.
Aarau Basel Bellinzona Bern Geneva Lausanne St. Gallen Zurich adult Zürich paed.
Total transplants
Total 280 974 202 591 365 888 207 1011 199
Allo 0 619 0 0 344 0 0 316 148
Auto 280 355 202 591 21 888 207 695 51
N male 162 592 139 386 229 537 105 639 127
% 57.9 60.8 68.8 65.3 62.7 60.5 50.7 63.2 63.8
Age: Allogeneic
median 40 44 44 7
(range) 0.74–69.6 2.75–69.9 16.7–68 0.16–23.3
Age: autologous
median 50 44 51 47 25 49 49 48 7.6
(range) 17.3–70.7 1.8–73.2 11.1–73 1.5–73.3 5.0–69.3 1.5–76.6 17.9–68.7 14.7–75.3 0.7–17.1
Main indication*
Leukaemia 39 (14%) 544 (56%) 18 (9%) 69 (12%) 264 (72%) 62 (7%) 7 (4%) 292 (29%) 69 (35%)
Lymphoma 196 (70%) 300 (31%) 171 (85%) 393 (66%) 69 (19%) 623 (70%) 170 (82%) 583 (58%) 8 (4%)
Nonmalignant 0 43 (4%) 0 0 17 (5%) 0 0 9 (1%) 83 (42%)
Solid tumour 45 (16%) 86 (9%) 13 (6%) 129 (22%) 15 (4%) 203 (23%) 30 (14%) 127 (12%) 38 (19)
EBMT risk score
0 2 13 3 1 9 3 0 2 18
1 12 58 9 16 28 26 6 40 53
2 51 185 34 116 74 177 33 158 83
3 106 290 61 255 85 353 80 360 36
4 76 243 72 167 85 256 67 310 7
5 33 147 23 36 56 73 21 132 2
6 34 27 9
7 4 1
Paediatric patients**
Allogeneic 0 98 0 0 34 0 0 5 141
Autologous 1 48 2 42 6 26 1 10 51
* Column percentage
** Defined as <18 years old at time of HSCT
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data were missing. Outcome was different for all-
ogeneic and autologous HSCT. Of the 1273 pa-
tients with an allogeneic HSCT, 761 (60%) were
alive, 480 (38%) had died, in 210 (44%) mortality
was transplantation-related, in 270 (56%) the
cause was relapse. 27 (2%) were lost to follow-up
and 5 had missing data. Of the 761 patients still
alive, 671 (88%) were alive without disease and 90
(12%) alive with relapse of disease. Of the 2535
patients with an autologous HSCT, 1526 (60%)
Figure 1
Survival- and
transplantation-
related mortality
of 3808 patients
with a ﬁrst HSCT
from 1997 to 2008
in Switzerland.
a) Probability of
survival by donor
type; b) Cumulative
incidence of
transplantation-
related mortality.
Survival estimates
according to Kaplan
and Meier
Autologous =
autologous (green)
HSCT (N = 2535)
Allogeneic =
allogeneic (blue)
HSCT (N = 1273).
Figure 2
Survival and
transplantation-
related mortality of
1273 patients with an
allogeneic HSCT from
1997 to 2008 in
Switzerland by EBMT
risk score.
Risk score 0–1, 2–3,
4–5, 6–7 (for
deﬁnition see
patients and
methods)
a) Probability
of survival.
b) Probability of
transplantation-
related mortality.
were alive, 940 (37%) had died, in 134 (14%) mor-
tality was transplantation-related, 806 (86%) had
died from relapse. 66 (3%) were lost to follow-up
and 3 had missing data. Of the 1526 patients still
alive, 1092 (72%) were disease-free and 434 (28%)
were in relapse of disease.
Despite the similarity of the absolute propor-
tions of patients alive (60%) between autologous
and allogeneic HSCT, probability of survival dif-
fers significantly between the two populations (fig.
1).The better early survival in patients with an au-
tologous HSCT (fig. 1a) due to the lower trans-
plantation-related mortality (fig. 1b) is offset later
on by the increase in relapse and relapse deaths.
This difference in outcome due to donor type
is further illustrated by the results of allogeneic
HSCT. Survival is best for HLA identical sibling
donor transplants due to the lower transplantation-
related mortality compared to mismatched family
donor or matched or mismatched unrelated donor
transplants with their higher transplantation-re-
lated mortality (data not shown).
Survival, transplantation-related mortality
and relapse were primarily influenced by the
EBMT risk score (fig. 2). Survival at day 100 and
at 5 years decreased with an increasing risk score.
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Figure 3
Survival probability
at 5 years depending
of the EBMT risk
score in the different
main disease
categories.
Acute leukaemia,
Lymphoma = lympho-
proliferative
disorders, Nonmalig-
nant = nonmalignant
diseases, Other = all
other indications.
a
b
a b
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This was due to the growing risk of transplanta-
tion-related mortality and relapse with increasing
risk score (fig. 2b). This effect of the EBMT risk
score on survival and transplantation-related mor-
tality was seen both for patients with allogeneic
(fig. 2a) and those with autologous HSCT (data
not shown). This effect of the EBMT risk score
was seen for all main disease categories, with dif-
ferent impact in the different disease categories
but a constant decrease in survival with increasing
risk score, due to increasing transplantation-re-
lated mortality and relapse death (fig. 3). In autol-
ogous HSCT the effects of risk score were more
pronounced for TRM than for survival.
Outcome by centre
Absolute and relative numbers of fatalities dif-
fered significantly between the nine participating
centres. Similarly, probability of survival of alloge-
neic HSCT (fig. 4a) and autologous HSCT (fig.
4b) showed marked differences.These differences
became minor when results were presented by
EBMT risk score, for allogeneic (fig. 4c) or autol-
ogous HSCT (fig. 4d). Using a Cox model of cen-
tre effect there were highly significant differences
in mortality among centres (p <0.0001) when
studied univariately; this difference decreased
considerably and was of borderline significance
only (p = 0.046) after adjustment for EBMT risk
score, underlying disease and year of transplant
for allogeneic HSCT. There was no significant
centre effect on overall mortality after autologous
HSCT in univariate or multivariate regression
models.
Figure 4b
Survival by centre, autologous HSCT.
Figure 4c
Probability of survival at 5 years, depending on EBMT risk
score and centre, allogeneic HSCT.
Figure 4a
Survival by centre, allogeneic HSCT.
Figure 4d
Probability of survival at 5 years, depending on EBMT risk
score and centre, autologous HSCT.
Figure 4
Survival- and
transplantation-
related mortality of
3808 patients with an
autologous or
allogeneic HSCT from
1997 to 2008 in
Switzerland by EBMT
risk score and
transplant centre.
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These data summarise the current activity and
outcome of HSCT in Switzerland. They docu-
ment the fact that all centres achieve a high qual-
ity and that data compare favourably with concur-
rent outcome in the literature from other coun-
tries. They also illustrate the danger of
centre-specific outcome reporting in a complex
field such as HSCT. A simple comparison of mor-
tality rates might suggest marked differences be-
tween the participating centres. This is not the
case and can be easily explained. The main differ-
ence in early mortality in patients with HSCT is
observed between autologous and allogeneic
HSCT, due to the more complex situation of an
allogeneic transplant with its associated early im-
munological complications of rejection, graft-ver-
sus-host disease and delayed immune reconstitu-
tion. Even though differences between centres re-
main, when the observation is restricted to either
autologous or allogeneic HSCT the centre effect
is most probably not due to “the centre” but the
case mix.Differences begin to fade merely with in-
tegration of the EBMT risk score into the analysis
[49, 50]. Five simple baseline pretransplant char-
acteristics, pooled in a score from 0–7 (0–5 for au-
tologous HSCT) – age of the patient, stage of the
disease, time interval from diagnosis to transplant
and (for allogeneic HSCT) donor type and donor
recipient gender combination – to a large extent
predict outcome.
This observation sends several independent
messages. First, the data suggest that the most
likely explanation for the differences observed are
differences in the case mix.This is in line with sev-
eral recent reports of outcome analyses in as dif-
ferent fields as HIV, stroke, surgery, or solid organ
transplantation [15, 35–44]. Differences in case
mix become obvious when centres with paediatric
or adult patients are compared. It is more difficult
when the treatment applies to apparently similar
patient populations. The EBMT risk score pro-
vides only a rough estimate. Several other inde-
pendent patient or disease risk factors have been
identified in HSCT, such as minor histocompati-
bility antigen differences, cytokine polymor-
phisms, ABO barrier, cytomegalovirus status,
Karnofski score, comorbidity index or molecular
features of the disease [51–55]. They are all estab-
lished risk factors with a well-defined impact on
outcome, none were included in the analysis; in-
formation on these factors was not routinely col-
lected.They could have had an impact on some of
the still observed differences, as has been discussed
in other comparative studies [56–58].
Similarly to these additional risk factors, treat-
ment modalities or transplant techniques were not
analysed in detail. There are differences between
bone marrow, cord blood and peripheral blood
stem cell products [3], and there are differences
between specified conditioning regimens and
graft-versus-host disease prevention or treatment
methods. Again, this information was not col-
lected in detail. However, as shown in large-scale
studies, they are more likely to have an impact on
short-term outcome with e.g. lower early TRM
with reduced intensity conditioning regimens, at
the expense of a higher relapse rate later on [50].
Considering only TRM at day 100 without inte-
grating conditioning intensity would falsify the
comparison.The absence of significant differences
between centres illustrates the difficulties in as-
sessing changes in use of transplant technologies.
It is wholly possible that strategy A confers an ad-
vantage compared to strategy B. To test the valid-
ity of such an assumption goes beyond the avail-
able numbers of patients in a country as small as
Switzerland. Comparison of crude mortality rates
remains inadequate or might even be dangerous.
It could prompt centres to refuse treatment for
high-risk patients, to avoid falling below a prede-
fined benchmark.
The second important and comforting mes-
sage is that all centres in Switzerland provide a
similar quality of care when measured by risk-ad-
justed outcome. This confirms the concept
adopted by the group, that all centres should fol-
low a strict and internationally recognised quality
management system, JACIE. The number of
transplants performed, beyond the priority mini-
mum, defined by JACIE as 10 HSCT per year,
should no longer be used as a criterion for politi-
cal decisions on transplant allocation. This does
not rule out the possibility that, for certain rare in-
dications as postulated for paediatric transplants
or HSCT for autoimmune disorders, numbers
will remain associated with outcome [22, 23, 48] It
remains an open question whether these few stud-
ies, e.g. HSCT for autoimmune disease, relate
more to the learning curve or the volume.
Lastly, the data illustrate the feasibility of a
mandatory data collection and data analysis sys-
tem within a complex field of medicine. This pro-
vides a basis for a network for collaboration and
exchange, a prime prerequisite for quality im-
provement [9, 15, 59–61]. As such, the HSCT da-
tabase in Switzerland and its management by
SBST may serve as a model for other fields of
high-cost or complex medicine in the future.
The authors would like to thank all contributing
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